НОВОЕ В КЛАССИФИКАЦИИ ВОЗ В-КЛЕТОЧНЫХ ОПУХОЛЕЙ ЛИМФОИДНОЙ ТКАНИ (ПЕРЕСМОТР 2016 г.)
Ключові слова:
классификация ВОЗ, В-клеточные лимфоидные новообразования.Анотація
Пересмотренная в 2016 г. классификация Всемирной организации здравоохранения В-клеточных лимфоидных новообразований, способствующая установлению уточненного диагноза на ранних стадиях заболевания,
включает иммуноцитохимические и молекулярно-генетические критерии
выделения многочисленных форм лимфом. Внесенные в классификацию изменения служат ключом для выбора стратегии терапии, направленной
на клетки-мишени.
Посилання
Swerdlow SH, Campo E, Harris NL, et al. (eds). WHO Classification of tumours of haematopoietic and lymphoid tissues.
Lyon: IARC Press, 2008. 439 p.
Swerdlow SH, Campo E, Pilery SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127 (20): 2375–90.
Nieto WG, Almeida J, Romero A, et al. Primary Health Care Group of Salamanca for the Study of MBL. Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood 2009; 114 (1): 33–7.
Xochelli A, Kalpadakis C, Gardiner A, et al. Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity? Blood 2014; 123 (8): 1199–206.
Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 364 (24): 2305–15.
Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med 2012; 367 (9): 826–33.
Swerdlow SH, Kuzu I, Dogan A, et al.The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Arch 2016; 468 (3): 259–75.
Schmidt J, Federmann B, Schindler N, et al. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. Br J Haematol 2015; 169 (6): 795–803.
Loeffler M, Kreuz M, Haake A, et al. HaematoSys-Project. Genomic and epigenomic co-evolution in follicular lymphomas. Leukemia 2015; 29 (2): 456–63.
Jegalian AG, Eberle FC, Pack SD, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood 2011; 118 (11): 2976–84.
Pillari RK, Surti U, Swerdlow SH. Follicular lymphomalike B cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies. Haematologica 2013; 98 (10): 1571–80.
Liu Q, Salaverria I, Pittaluga S, et al. Follicular lymphomas in children and young adults: a comparison of the pediatric
variant with usual follicular lymphoma. Am J Surg Pathol 2013; 37 (3): 333–43.
Schmatz AI, Streubel B, Kretschmer-Chott E, et al. Primary follicular lymphoma of the duodenum is a distinct mucosal/ submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol 2011; 29 (11): 1445–51.
Katzenberger T, Kalla J, Leich E, et al. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood 2009; 113 (5): 1053–61.
Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 2012; 122 (10):
–23.
Beà S, Valdés-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.
Proc Natl Acad Sci USA 2013; 110 (45): 18250–5.
Carvajal-Cuenca A, Sua LF, Silva NM, et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 2012; 97 (2): 270–8.
Young RM, Shaffer AL, Phelan JD, Staudt LM. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol 2015; 52 (2): 77–85.
Pasqualucci L, Dalla-Favera R. The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol 2015; 52 (2): 67–76.
Roschewski M, Staudt LM, Wilson WH. Diffuse large Bcell lymphoma-treatment approaches in the molecular era. Nat
Rev Clin Oncol 2014; 11 (1): 12–23.
Nicolae A, Pittaluga S, Abdullah S, et al.EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood 2015; 126 (7): 863–72.
Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer — a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol 2010; 34 (3): 405–17.
Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012; 44 (12): 1321–25.
Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117 (19): 5019–32.
Campo E. MYC in DLBCL: partners matter. Blood 2015; 126 (22): 2439–40.
Momose S, Weißbach S, Pischimarov J, et al. The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum. Leukemia 2015; 29 (8): 1789–91.
